Post-Test Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies Post-Test Which of the following biomarker tests can be used to select patients for HER2-targeted therapy? Companion Diagnostic Device Immunohistochemistry (IHC) Reverse Transcription Polymerase Chain Reaction (RT-PCR) RNA-Based Multiplexed Assay In the phase 2 MOUNTAINEER trial assessing tucatinib plus trastuzumab in previously treated patients with HER2-positive mCRC, which of the following outcomes was observed? Clinically meaningful and durable tumor responses in patients treated with tucatinib plus trastuzumab Maintenance of quality-of-life outcomes in tucatinib plus trastuzumab group Similar ORR in the tucatinib plus trastuzumab group and the tucatinib monotherapy group Trend towards improvement in OS in patients treated with tucatinib plus trastuzumab Which of the following is seen most often in patients with CRC taking HER2-targeted agents and may lead to discontinuation of treatment? Alopecia Diarrhea Renal Toxicity Tinnitus How often will you perform complete biomarker testing for patients with mCRC? Always Often Sometimes Rarely Never How confident are you in your ability to integrate HER2-targeted therapies into clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
